Middle East And Africa Multiple Hereditary Exostosis Market
市场规模（十亿美元）
CAGR :
% 
USD
4.80 Million
USD
6.51 Million
2024
2032
 Forecast Period |
2025 –2032 |
 Market Size (Base Year) |
USD 4.80 Million |
 Market Size (Forecast Year) |
USD 6.51 Million |
 CAGR |
% |
| Major Markets Players |
|
中東和非洲多發性遺傳性外生骨疣市場細分，按類型（無蒂和帶蒂）、治療（手術、藥物和其他）、診斷（X 光、電腦斷層掃描 (CT)、磁振造影 (MRI)、基因檢測和其他）、部位（腿、手臂、肩膀、骨盆、手指和腳趾）、年齡組（兒童和成人診所）、最終用戶（診間 20 年）。
中東和非洲多發性遺傳性外生骨疣市場規模
- 2024 年，中東和非洲多發性遺傳性外生骨疣市場規模為480 萬美元 ，預計 到 2032 年將達到 651 萬美元，預測期內 複合年增長率為 3.90%。
- 市場成長主要得益於對罕見遺傳疾病認識的提高、診斷基礎設施的改善以及整個地區基因檢測技術的逐步進步
- 此外，政府和非營利組織對罕見疾病研究的支持不斷增加，以及對個人化和精準醫療的投資不斷增加，為MHE的早期診斷和治療創造了更有利的環境。這些因素共同推動了標靶治療和基因服務的穩定發展，從而推動了中東和非洲地區市場的成長軌跡。
中東和非洲多發性遺傳性外生骨疣市場分析
- 多發性遺傳性外生骨疣 (MHE) 是一種罕見的遺傳性疾病，其特徵是多個良性骨腫瘤的生長。由於診斷能力的提高、患者權益的增強以及整個地區對罕見疾病醫療保健需求的日益關注，該疾病在中東和非洲地區越來越受到關注。
- 隨著醫療保健提供者和患者意識的提高，以及遺傳諮詢和影像技術的應用範圍的擴大，對 MHE 早期診斷和先進治療方案的需求也隨之增加
- 2024 年，南非在中東和非洲多發性遺傳性外生骨疣市場佔據主導地位，收入份額最高，為 28.9%，這得益於其相對先進的醫療基礎設施、積極的遺傳性疾病研究項目以及治療罕見疾病的專門醫療機構
- 由於政府醫療支出增加、醫療旅遊成長以及罕見疾病登記和精準醫療計畫的啟動，預計阿拉伯聯合大公國 (UAE) 將成為預測期內中東和非洲多發性遺傳性外生骨疣市場成長最快的國家
- 無柄型外生骨疣在中東和非洲多發性遺傳性外生骨疣市場佔據主導地位，2024 年的市佔率為 55.2%，這得益於其在患者中的盛行率較高，且更容易透過標準影像技術檢測
報告範圍和中東和非洲多發性遺傳性外生骨疣市場細分
|
屬性 |
中東和非洲多發性遺傳性外生骨疣關鍵市場洞察 |
|
涵蓋的領域 |
|
|
覆蓋國家 |
中東和非洲
|
|
主要市場參與者 |
|
|
市場機會 |
|
|
加值資料資訊集 |
除了對市場價值、成長率、細分、地理覆蓋範圍和主要參與者等市場情景的洞察之外，Data Bridge Market Research 策劃的市場報告還包括深入的專家分析、定價分析、品牌份額分析、消費者調查、人口統計分析、供應鏈分析、價值鏈分析、原材料/消耗品概述、供應商選擇標準、PESTLE 分析、波特分析和監管框架。 |
中東和非洲多發性遺傳性外生骨疣市場趨勢
“基因檢測和早期診斷的進展”
- 中東和非洲多發性遺傳性外生骨疣 (MHE) 市場的一個重要且加速的趨勢是越來越多地採用先進的基因檢測和成像技術，這增強了該地區受影響個體的早期診斷和個性化護理策略
- 例如，阿聯酋和南非等國的領先醫療機構正越來越多地將新一代定序 (NGS) 和基於 MRI 的監測納入 MHE 等罕見骨骼疾病的標準護理實踐中
- 基因檢測能夠及早發現導致MHE的EXT1和EXT2基因突變，進而促進及時介入並改善臨床療效。沙烏地阿拉伯和埃及的機構已開始與國際基因實驗室合作，以擴大這些診斷工具的可近性。
- 三級醫療中心配備 MRI 和 CT 掃描，可以準確繪製腫瘤生長和骨骼畸形的影像，從而支持更好的手術計劃和長期監測
- 這些診斷技術的進步正在推動疾病管理向更主動的轉變，使醫療保健提供者能夠設計個人化的治療途徑並延緩或預防功能障礙
- 隨著醫療專業人員和患者對 MHE 認識的不斷提高，對全面診斷評估的需求預計將會增加，從而進一步加強精準醫療在 MEA 地區罕見疾病領域的作用
中東和非洲多發性遺傳性外生骨疣市場動態
司機
“日益增強的意識、專業的護理和政府的支持性政策”
- 人們對 MHE 等罕見遺傳疾病的認識不斷提高，加上醫療基礎設施的改善和專科護理中心的普及，正在推動中東和非洲市場的成長
- 例如，南非政府資助的罕見疾病計畫和遺傳諮詢計畫大大提高了 MHE 患者的早期發現和治療機會
- 沙烏地阿拉伯和阿聯酋等國政府努力投資罕見疾病登記，推廣基因組醫學，並改善骨科手術和物理治療的可及性，為市場擴張創造有利環境
- 倡導團體和醫療推廣計劃的不斷增加也有助於減少恥辱感，並提高患者對未治療的 MHE 的長期影響的教育
- 海灣地區專業骨科中心的醫療旅遊成長是導致外科治療和術後復健服務需求不斷增長的另一個因素
克制/挑戰
“基因檢測成本高，偏遠地區民眾認知度有限”
- 儘管取得了進展，但基因檢測和專業影像工具的高成本仍然限制了早期 MHE 診斷的廣泛普及，尤其是在低收入和農村地區
- 撒哈拉以南非洲的許多國家仍然面臨著診斷基礎設施的巨大差距，CT 或 MRI 機器的供應有限，缺乏訓練有素的遺傳諮詢師或骨科專家
- 由於疾病較為罕見，且一些地區缺乏全國性的宣傳活動，經常導致診斷延遲、誤診或長期照護不足，從而導致患者預後惡化
- 手術和後續護理的自付費用可能相當高，尤其是在保險覆蓋範圍有限或政府對罕見疾病缺乏支持的系統中
- 克服這些挑戰需要跨部門合作、增加對罕見疾病計畫的公私資助，以及擴大醫療專業人員在識別和管理 MHE 等遺傳性骨骼疾病方面的培訓
中東和非洲多發性遺傳性外生骨疣市場範圍
市場根據類型、治療、診斷、地點、年齡層和最終用戶進行細分。
- 按類型
根據類型，中東和非洲的多發性遺傳性外生骨疣市場分為無蒂型和帶蒂型。無蒂型佔市場主導地位，2024年的收入份額最高，達55.2%，這得益於其在多發性骨軟骨瘤 (MHE) 病例中的患病率更高，且透過X光和MRI等診斷影像檢查更容易識別。無蒂型骨軟骨瘤由於基底較寬，且更容易發生神經壓迫或畸形等併發症，通常需要更密切的監測和介入。這增加了與該亞型相關的診斷和治療需求。
由於影像可及性的提高使得人們能夠更好地識別和區分骨骼病變類型，尤其是在專科診所和城市醫院，預計帶蒂骨病變部分將在 2025 年至 2032 年間經歷最快的複合年增長率。
- 按治療
根據治療方法，中東和非洲多發性遺傳性外生骨疣市場細分為手術、藥物治療和其他治療。 2024年，手術治療佔了最高的市場份額，這是因為手術切除仍然是症狀性骨軟骨瘤的主要治療方法，尤其是那些引起疼痛、畸形或功能障礙的骨軟骨瘤。區域醫院骨科專科化程度的提高以及前往阿聯酋和南非等國的醫療旅遊也為此細分市場提供了支持。
預計2025年至2032年期間，藥物領域將迎來最快的複合年增長率，主要用於疼痛管理或發炎控制，儘管仍具有輔助作用而非治療作用。基因標靶治療和支持性藥物治療的創新或將促進該領域的長期成長。
- 按診斷
根據診斷，中東和非洲多發性遺傳性外生骨疣市場細分為X光、電腦斷層掃描 (CT)、磁振造影 (MRI)、基因檢測等。 X射線因其在檢測與多發性遺傳性外生骨疣 (MHE) 相關的骨質增生方面的廣泛可用性和成本效益而引領市場。它通常是公立和私立醫療機構的第一線診斷工具。
預計到2032年，MRI將實現最快的成長速度，因為它能夠更詳細地顯示軟骨帽和軟組織受累情況，這對於手術規劃至關重要。沙烏地阿拉伯、阿聯酋和埃及等國城市中心對先進診斷基礎設施的投資不斷增加，也支持了這一趨勢。
- 按站點
根據發病部位，中東和非洲多發性遺傳性外生骨疣市場可細分為腿部、手臂、肩部、骨盆、手指和腳趾。 2024年，腿部畸形佔最大份額，因為下肢畸形是多發性遺傳性外生骨疣患者最常見的畸形，常導致步態障礙和骨科幹預。對矯正腿長差異和角度畸形的關注推動了早期診斷和矯正手術的需求。
預計從 2025 年到 2032 年，手臂和肩部部位的複合年增長率將最快，尤其是在兒童患者中，因為這些部位常見與生長相關的併發症。
- 按年齡組
根據年齡組，中東和非洲多發性遺傳性外生骨疣市場分為兒童和成人。 2024年，兒童市場佔據主導地位，因為多發性遺傳性外生骨疣是一種遺傳性疾病，通常在兒童早期發病，並在青春期前出現明顯症狀。兒童患者在成長過程中通常需要長期監測和多種幹預措施，因此該群體對診斷和治療服務的需求更高。
由於對晚期或先前未確診病例的診斷增加，以及對兒童 MHE 倖存者的持續監測，預計成人部分將在 2025 年至 2032 年間見證最快的複合年增長率。
- 按最終用戶
根據最終用戶，中東和非洲多發性遺傳性外生骨疣市場細分為醫院、專科診所、門診手術中心和其他類型。 2024年，醫院領域佔據最大市場份額，引領市場，因為大多數外科手術和高級診斷服務都集中在擁有多學科專業知識的醫院環境中。
預計專科診所將在預測期內實現最快成長，這得益於沙烏地阿拉伯、阿聯酋和南非等城市中心地區專注於罕見疾病的骨科和遺傳診所數量的不斷增加。這些診所提供以患者為中心的專業護理，診斷速度更快，並能提供外科專業知識。
中東和非洲多發性遺傳性外生骨疣市場區域分析
- 2024 年，南非在中東和非洲多發性遺傳性外生骨疣市場佔據主導地位，收入份額最高，為 28.9%，這得益於其相對先進的醫療基礎設施、積極的遺傳性疾病研究項目以及治療罕見疾病的專門醫療機構
- 該國的醫療保健系統優先考慮早期診斷和個人化護理，尤其是在領先的城市醫院和研究中心，核磁共振成像、基因檢測和專門的骨科治療的普及率不斷提高
- 國家衛生策略進一步加強了這一區域領導地位，這些策略旨在提高人們對罕見疾病的認識，擴大患者登記，並加強當地機構和國際研究機構之間的合作，使沙烏地阿拉伯成為整個中東和非洲地區 MHE 診斷和治療的重要樞紐
沙烏地阿拉伯多發性遺傳性外生骨疣市場洞察
2024年，沙烏地阿拉伯多發性遺傳性外生骨疣市場佔據了該地區最大的收入份額，這得益於政府對基因組醫學、專科骨科護理和罕見疾病研究的大力投入。國家級基因篩檢計畫的啟動以及MRI和CT掃描等先進診斷技術的普及，顯著加強了早期多發性遺傳性外生骨疣的識別和治療。此外，沙烏地醫療機構與國際研究組織之間的合作正在提升臨床療效，並促進罕見疾病管理領域的創新。
阿聯酋多發性遺傳性外生骨疣市場洞察
預計阿聯酋多發性遺傳性外生骨疣市場在預測期內將實現顯著的複合年增長率，這得益於醫療旅遊業的發展、人們對遺傳疾病認識的提高以及人均醫療保健支出的增加。世界一流的專科診所以及早期外科治療的便利，使阿聯酋成為海灣地區多發性遺傳性外生骨疣治療的中心。政府主導的精準醫療計畫以及罕見疾病公眾教育的加強，進一步支撐了市場的上升趨勢。
南非多發性遺傳性外生骨疣市場洞察
由於對罕見疾病診斷的日益重視以及公共醫療服務可近性的提高，南非多發性遺傳性外生骨疣市場正在穩步擴張。該國將遺傳諮詢和影像診斷整合到三級醫院，提高了罕見疾病的檢出率。儘管農村地區仍面臨挑戰，但城市中心對兒科骨科護理的需求正在不斷增長，這對於管理多發性遺傳性外生骨疣至關重要。與國際組織的合作也有助於提升南非罕見疾病的研究能力。
埃及多發性遺傳性外生骨疣市場洞察
埃及多發性遺傳性外生骨疣市場正日益受到關注，這得益於該國對醫療改革的戰略重點以及將罕見疾病納入國家政策框架。學術醫療中心越來越多地配備了基因檢測和核磁共振成像等診斷技術，從而能夠更準確地識別患者。公共衛生倡議和醫生培訓計畫正在逐步提高公眾意識，同時，與非政府組織和區域研究機構的合作也有助於彌合醫療資源匱乏人群的醫療差距。
中東和非洲多發性遺傳性外生骨疣市場份額
中東和非洲多發性遺傳性外生骨疣產業主要由知名公司主導，其中包括：
- Illumina公司（美國）
- 美敦力（愛爾蘭）
- Zimmer Biomet Holdings, Inc.（美國）
- 史賽克（美國）
- 西門子醫療股份公司（德國）
- GE醫療科技公司（美國）
- 佳能醫療系統株式會社（日本）
- Esaote SpA（義大利）
- 賽默飛世爾科技公司（美國）
- 羅氏控股公司（瑞士）
- Koninklijke Philips NV（荷蘭）
- B.Braun Melsungen AG（德國）
- 安捷倫科技公司（美國）
- 珀金埃爾默公司（美國）
- 富士軟片株式會社（日本）
- 北京華大基因（BGI Genomics）（中國）
- 深圳邁瑞生物醫療電子股份有限公司 (中國)
- 江蘇特勞泰克醫療科技有限公司 (中國)
- 東芝公司（日本）
- Takara Bio Inc.（日本）
中東和非洲多發性遺傳性外骨疣市場的最新發展如何？
- 2024年5月，沙烏地阿拉伯費薩爾國王專科醫院及研究中心啟動了一家專門的罕見骨病診所，專注於治療多發性遺傳性外生骨疣等疾病。該計劃旨在透過遺傳諮詢、骨科幹預和長期隨訪提供全面護理，反映了沙烏地阿拉伯對兒科罕見疾病專科治療和早期診斷的日益重視。
- 2024年4月，Mediclinic Middle East (UAE) 與國際基因組學實驗室達成合作，旨在提升 EXT1 和 EXT2 基因突變檢測的可及性，從而簡化 MHE 的早期準確診斷。此次合作增強了當地診所提供精準醫療的能力，並凸顯了該地區對個人化醫療的追求。
- 2024年3月，南非格魯特舒爾醫院啟動了一項試點項目，整合了基於MRI的軟骨帽監測技術，用於兒童多發性硬化性腦脊髓炎（MHE）患者。該計畫預計將改善手術規劃和長期骨科療效，標誌著公共衛生領域向更積極主動、數據驅動的MHE護理轉型。
- 2024年2月，埃及衛生部在公立醫院和兒科診所開展了一項全國性的遺傳性骨骼疾病（包括MHE）的宣傳活動。該活動重點關注早期症狀識別和轉診方案，旨在減少診斷延誤，並改善醫療資源匱乏地區的患者預後。
- 2024年1月，支持罕見疾病管理的非營利聯盟CureRare Africa在肯亞和奈及利亞啟動了MHE註冊試點項目，以追蹤盛行率、治療途徑和患者預後。這種數據驅動的方法支持臨床研究和倡導工作，幫助彌合非洲大陸的醫療差距，並促進醫療服務提供者、研究人員和政策制定者之間的合作。
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET END USER COVERAGE GRID
2.8 PRODUCT LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTER’S FIVE FORCES
4.2 PESTEL ANALYSIS
4.3 PIPELINE ANALYSIS - OBSERVATORY DATA
4.4 EPIDEMIOLOGY
5 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: REGULATIONS
5.1 REGULATION IN UNITED STATES: U.S. FOOD AND DRUG ADMINISTRATION (FDA)
5.1.1 REGULATION IN EUROPE: EUROPEAN MEDICINES AGENCY (EMA)
5.2 REGULATION IN ASIA-PACIFIC (JAPAN): PHARMACEUTICAL AND MEDICAL DEVICES AGENCY (PMDA)
5.3 MEDICAL DEVICE STANDARDS
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 RISING PREVALENCE OF GENETIC DISORDERS
6.1.2 GROWING PEDIATRIC POPULATION
6.1.3 DEVELOPMENT OF NOVEL THERAPIES
6.2 RESTRAINTS
6.2.1 HIGH COST OF ADVANCED THERAPIES
6.2.2 LIMITED AVAILABILITY OF THERAPIES
6.3 OPPORTUNITIES
6.3.1 INCREASE IN PATIENT CARE AND SUPPORT SYSTEMS
6.3.2 INCREASE IN THE NUMBER OF COLLABORATIONS AND PARTNERSHIPS
6.4 CHALLENGES
6.4.1 LIMITED AWARENESS ABOUT THE DISORDER
6.4.2 LACK OF DRUG APPROVALS ASSOCIATED WITH THE DISORDER
7 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE
7.1 OVERVIEW
7.2 SESSILE
7.3 PEDUNCULATED
8 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TREATMENT
8.1 OVERVIEW
8.2 SURGERY
8.2.1 REMOVE THE TUMOR
8.2.2 LENGTHEN LIMBS
8.3 MEDICATION
8.3.1 HOSPITAL PHARMACIES
8.3.2 DRUGS STORES AND RETAIL PHARMACIES
8.3.3 ONLINE PHARMACIES
8.4 OTHERS
9 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DIAGNOSIS
9.1 OVERVIEW
9.2 X-RAY
9.2.1 SESSILE
9.2.2 PEDUNCULATED
9.3 COMPUTED TOMOGRAPHY (CT) SCAN
9.3.1 SESSILE
9.3.2 PEDUNCULATED
9.4 MAGNETIC RESONANCE IMAGING (MRI)
9.4.1 SESSILE
9.4.2 PEDUNCULATED
9.5 GENETIC TESTS
9.5.1 SESSILE
9.5.2 PEDUNCULATED
9.6 OTHERS
9.6.1 SESSILE
9.6.2 PEDUNCULATED
10 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY SITE
10.1 OVERVIEW
10.2 LEGS
10.3 ARMS
10.4 SHOULDERS
10.5 PELVIS
10.6 FINGERS
10.7 TOES
11 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY AGE GROUP
11.1 OVERVIEW
11.2 PEDIATRIC
11.3 ADULT
12 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY END USER
12.1 OVERVIEW
12.2 HOSPITAL
12.2.1 PRIVATE
12.2.2 GOVERNMENT
12.3 SPECIALTY CLINICS
12.4 AMBULATORY SURGICAL CENTERS
12.5 OTHERS
13 MIDDLE EAST AND AFRICA MULTIPLE HEREDITY EXOSTOSIS MARKET, BY REGION
13.1 MIDDLE EAST AND AFRICA
13.1.1 SAUDI ARABIA
13.1.2 U.A.E.
13.1.3 EGYPT
13.1.4 KUWAIT
13.1.5 QATAR
13.1.6 OMAN
13.1.7 BAHRAIN
13.1.8 REST OF MIDDLE EAST AND AFRICA
14 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA
15 SWOT ANALYSIS
16 COMPANY PROFILES
16.1 BAYERS AG
16.1.1 COMPANY SNAPSHOT
16.1.2 REVENUE ANALYSIS
16.1.3 COMPANY SHARE ANALYSIS
16.1.4 PRODUCT PORTFOLIO
16.1.5 RECENT UPDATES
16.2 HALEON GROUP OF COMPANIES
16.2.1 COMPANY SNAPSHOT
16.2.2 REVENUE ANALYSIS
16.2.3 COMPANY SHARE ANALYSIS
16.2.4 PRODUCT PORTFOLIO
16.2.5 RECENT DEVELOPMENTS
16.3 BASF
16.3.1 COMPANY SNAPSHOT
16.3.2 REVENUE ANALYSIS
16.3.3 COMPANY SHARE ANALYSIS
16.3.4 PRODUCT PORTFOLIO
16.3.5 RECENT UPDATES
16.4 VIATRIS INC.
16.4.1 COMPANY SNAPSHOT
16.4.2 REVENUE ANALYSIS
16.4.3 COMPANY SHARE ANALYSIS
16.4.4 PRODUCT PORTFOLIO
16.4.5 RECENT UPDATES
16.5 ACTIZAPHARMA
16.5.1 COMPANY SNAPSHOT
16.5.2 PRODUCT PORTFOLIO
16.5.3 RECENT UPDATES
16.6 ADVACARE PHARMA
16.6.1 COMPANY SNAPSHOT
16.6.2 PRODUCT PORTFOLIO
16.6.3 RECENT UPDATES
16.7 AUROBINDO PHARMA
16.7.1 COMPANY SNAPSHOT
16.7.2 REVENUE ANALYSIS
16.7.3 PRODUCT PORTFOLIO
16.7.4 RECENT TABLETS
16.8 HALEON GROUP OF COMPANIES
16.8.1 COMPANY SNAPSHOT
16.8.2 REVENUE ANALYSIS
16.8.3 PRODUCT PORTFOLIO
16.8.4 RECENT UPDATES
16.9 IPSEN BIOPHARMACEUTICALS, INC.
16.9.1 COMPANY SNAPSHOT
16.9.2 REVENUE ANALYSIS
16.9.3 PRODUCT PORTFOLIO
16.9.4 RECENT UPDATES
16.1 MALLINCKRODT
16.10.1 COMPANY SNAPSHOT
16.10.2 REVENUE ANALYSIS
16.10.3 PRODUCT PORTFOLIO
16.10.4 RECENT UPDATES
16.11 TEVA PHARMACEUTICAL INDUSTRIES LTD.
16.11.1 COMPANY SNAPSHOT
16.11.2 REVENUE ANALYSIS
16.11.3 PRODUCT PORTFOLIO
16.11.4 RECENT UPDATES
16.12 TAJ PHARMACEUTICALS LIMITED
16.12.1 COMPANY SNAPSHOT
16.12.2 PRODUCT PORTFOLIO
16.12.3 RECENT UPDATES
17 QUESTIONNAIRE
18 RELATED REPORTS
表格列表
TABLE 1 PIPELINE ANALYSIS - OBSERVATORY DATA
TABLE 2 PIPELINE ANALYSIS - INTERVENTIONAL DATA
TABLE 3 SALES DATA - 2024
TABLE 4 SALES DATA - 2023
TABLE 5 SALES DATA - 2022
TABLE 6 SALES DATA - 2021
TABLE 7 SALES DATA - 2020
TABLE 8 SALES DATA - 2019
TABLE 9 SALES DATA - 2018
TABLE 10 COST OF PALOVAROTENE
TABLE 11 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 12 MIDDLE EAST AND AFRICA SESSILE IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 13 MIDDLE EAST AND AFRICA PEDUNCULATED IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 14 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 15 MIDDLE EAST AND AFRICA SURGERY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 16 MIDDLE EAST AND AFRICA SURGERY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 17 MIDDLE EAST AND AFRICA MEDICATION IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 18 MIDDLE EAST AND AFRICA MEDICATION IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 19 MIDDLE EAST AND AFRICA MEDICATION IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 20 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DIAGNOSIS, 2022-2031 (USD THOUSAND)
TABLE 21 MIDDLE EAST AND AFRICA X-RAY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 22 MIDDLE EAST AND AFRICA X-RAY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 23 MIDDLE EAST AND AFRICA COMPUTED TOMOGRAPHY (CT) SCAN IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 24 MIDDLE EAST AND AFRICA COMPUTED TOMOGRAPHY (CT) SCAN IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 25 MIDDLE EAST AND AFRICA MAGNETIC RESONANCE IMAGING (MRI) IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 26 MIDDLE EAST AND AFRICA MAGNETIC RESONANCE IMAGING (MRI) IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 27 MIDDLE EAST AND AFRICA GENETIC TESTS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 28 MIDDLE EAST AND AFRICA GENETIC TESTS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 29 MIDDLE EAST AND AFRICA OTHERS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 30 MIDDLE EAST AND AFRICA OTHERS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 31 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY SITE, 2022-2031 (USD THOUSAND)
TABLE 32 MIDDLE EAST AND AFRICA LEGS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 33 MIDDLE EAST AND AFRICA ARMS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 34 MIDDLE EAST AND AFRICA SHOULDERS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 35 MIDDLE EAST AND AFRICA PELVIS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 36 MIDDLE EAST AND AFRICA FINGERS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 37 MIDDLE EAST AND AFRICA TOES IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 38 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 39 MIDDLE EAST AND AFRICA PEDIATRIC IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 40 MIDDLE EAST AND AFRICA ADULT IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 41 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 42 MIDDLE EAST AND AFRICA HOSPITAL IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 43 MIDDLE EAST AND AFRICA HOSPITAL IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 44 MIDDLE EAST AND AFRICA SPECIALTY CLINICS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 45 MIDDLE EAST AND AFRICA AMBULATORY SURGICAL CENTERS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 46 MIDDLE EAST AND AFRICA OTHERS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 47 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)
TABLE 48 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 49 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 50 MIDDLE EAST AND AFRICA SURGERY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 51 MIDDLE EAST AND AFRICA MEDICATION IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 52 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DIAGNOSIS, 2022-2031 (USD THOUSAND)
TABLE 53 MIDDLE EAST AND AFRICA X-RAY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 54 MIDDLE EAST AND AFRICA COMPUTED TOMOGRAPHY (CT) SCAN IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 55 MIDDLE EAST AND AFRICA MAGNETIC RESONANCE IMAGING (MRI) IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 56 MIDDLE EAST AND AFRICA GENETIC TESTS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 57 MIDDLE EAST AND AFRICA OTHERS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 58 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY SITE, 2022-2031 (USD THOUSAND)
TABLE 59 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 60 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 61 MIDDLE EAST AND AFRICA HOSPITAL IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 62 SAUDI ARABIA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 63 SAUDI ARABIA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 64 SAUDI ARABIA SURGERY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 65 SAUDI ARABIA MEDICATION IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 66 SAUDI ARABIA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DIAGNOSIS, 2022-2031 (USD THOUSAND)
TABLE 67 SAUDI ARABIA X-RAY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 68 SAUDI ARABIA COMPUTED TOMOGRAPHY (CT) SCAN IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 69 SAUDI ARABIA MAGNETIC RESONANCE IMAGING (MRI) IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 70 SAUDI ARABIA GENETIC TESTS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 71 SAUDI ARABIA OTHERS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 72 SAUDI ARABIA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY SITE, 2022-2031 (USD THOUSAND)
TABLE 73 SAUDI ARABIA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 74 SAUDI ARABIA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 75 SAUDI ARABIA HOSPITAL IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 76 SOUTH AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 77 SOUTH AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 78 SOUTH AFRICA SURGERY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 79 SOUTH AFRICA MEDICATION IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 80 SOUTH AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DIAGNOSIS, 2022-2031 (USD THOUSAND)
TABLE 81 SOUTH AFRICA X-RAY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 82 SOUTH AFRICA COMPUTED TOMOGRAPHY (CT) SCAN IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 83 SOUTH AFRICA MAGNETIC RESONANCE IMAGING (MRI) IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 84 SOUTH AFRICA GENETIC TESTS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 85 SOUTH AFRICA OTHERS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 86 SOUTH AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY SITE, 2022-2031 (USD THOUSAND)
TABLE 87 SOUTH AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 88 SOUTH AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 89 SOUTH AFRICA HOSPITAL IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 90 U.A.E. MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 91 U.A.E. MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 92 U.A.E. SURGERY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 93 U.A.E. MEDICATION IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 94 U.A.E. MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DIAGNOSIS, 2022-2031 (USD THOUSAND)
TABLE 95 U.A.E. X-RAY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 96 U.A.E. COMPUTED TOMOGRAPHY (CT) SCAN IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 97 U.A.E. MAGNETIC RESONANCE IMAGING (MRI) IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 98 U.A.E. GENETIC TESTS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 99 U.A.E. OTHERS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 100 U.A.E. MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY SITE, 2022-2031 (USD THOUSAND)
TABLE 101 U.A.E. MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 102 U.A.E. MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 103 U.A.E. HOSPITAL IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 104 EGYPT MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 105 EGYPT MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 106 EGYPT SURGERY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 107 EGYPT MEDICATION IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 108 EGYPT MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DIAGNOSIS, 2022-2031 (USD THOUSAND)
TABLE 109 EGYPT X-RAY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 110 EGYPT COMPUTED TOMOGRAPHY (CT) SCAN IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 111 EGYPT MAGNETIC RESONANCE IMAGING (MRI) IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 112 EGYPT GENETIC TESTS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 113 EGYPT OTHERS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 114 EGYPT MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY SITE, 2022-2031 (USD THOUSAND)
TABLE 115 EGYPT MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 116 EGYPT MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 117 EGYPT HOSPITAL IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 118 KUWAIT MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 119 KUWAIT MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 120 KUWAIT SURGERY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 121 KUWAIT MEDICATION IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 122 KUWAIT MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DIAGNOSIS, 2022-2031 (USD THOUSAND)
TABLE 123 KUWAIT X-RAY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 124 KUWAIT COMPUTED TOMOGRAPHY (CT) SCAN IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 125 KUWAIT MAGNETIC RESONANCE IMAGING (MRI) IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 126 KUWAIT GENETIC TESTS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 127 KUWAIT OTHERS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 128 KUWAIT MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY SITE, 2022-2031 (USD THOUSAND)
TABLE 129 KUWAIT MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 130 KUWAIT MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 131 KUWAIT HOSPITAL IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 132 QATAR MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 133 QATAR MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 134 QATAR SURGERY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 135 QATAR MEDICATION IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 136 QATAR MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DIAGNOSIS, 2022-2031 (USD THOUSAND)
TABLE 137 QATAR X-RAY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 138 QATAR COMPUTED TOMOGRAPHY (CT) SCAN IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 139 QATAR MAGNETIC RESONANCE IMAGING (MRI) IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 140 QATAR GENETIC TESTS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 141 QATAR OTHERS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 142 QATAR MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY SITE, 2022-2031 (USD THOUSAND)
TABLE 143 QATAR MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 144 QATAR MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 145 QATAR HOSPITAL IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 146 OMAN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 147 OMAN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 148 OMAN SURGERY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 149 OMAN MEDICATION IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 150 OMAN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DIAGNOSIS, 2022-2031 (USD THOUSAND)
TABLE 151 OMAN X-RAY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 152 OMAN COMPUTED TOMOGRAPHY (CT) SCAN IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 153 OMAN MAGNETIC RESONANCE IMAGING (MRI) IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 154 OMAN GENETIC TESTS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 155 OMAN OTHERS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 156 OMAN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY SITE, 2022-2031 (USD THOUSAND)
TABLE 157 OMAN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 158 OMAN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 159 OMAN HOSPITAL IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 160 BAHRAIN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 161 BAHRAIN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 162 BAHRAIN SURGERY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 163 BAHRAIN MEDICATION IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 164 BAHRAIN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DIAGNOSIS, 2022-2031 (USD THOUSAND)
TABLE 165 BAHRAIN X-RAY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 166 BAHRAIN COMPUTED TOMOGRAPHY (CT) SCAN IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 167 BAHRAIN MAGNETIC RESONANCE IMAGING (MRI) IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 168 BAHRAIN GENETIC TESTS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 169 BAHRAIN OTHERS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 170 BAHRAIN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY SITE, 2022-2031 (USD THOUSAND)
TABLE 171 BAHRAIN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 172 BAHRAIN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 173 BAHRAIN HOSPITAL IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 174 REST OF MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
图片列表
FIGURE 1 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: MIDDLE EAST AND AFRICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: MARKET END USER COVERAGE GRID
FIGURE 8 PRODUCT LIFELINE CURVE
FIGURE 9 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: DBMR MARKET POSITION GRID
FIGURE 10 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: VENDOR SHARE ANALYSIS
FIGURE 11 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: SEGMENTATION
FIGURE 12 EXECUTIVE SUMMARY
FIGURE 13 STRATEGIC DECISIONS
FIGURE 14 TWO SEGMENTS COMPRISE THE MIDDLE EAST AND AFRICA MULTIPLE HEREDITY EXOSTOSIS MARKET, BY TYPE
FIGURE 15 RISING PREVALENCE OF GENETIC DISORDERS IS DRIVING THE GROWTH OF THE MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET FROM 2024 TO 2031
FIGURE 16 THE TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET IN 2024 AND 2031
FIGURE 17 MARKET OVERVIEW
FIGURE 18 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY TYPE, 2023
FIGURE 19 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY TYPE, 2024-2031 (USD THOUSAND)
FIGURE 20 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY TYPE, CAGR (2024-2031)
FIGURE 21 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY TYPE, LIFELINE CURVE
FIGURE 22 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY TREATMENT, 2023
FIGURE 23 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY TREATMENT, 2024-2031 (USD THOUSAND)
FIGURE 24 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY TREATMENT, CAGR (2024-2031)
FIGURE 25 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY TREATMENT, LIFELINE CURVE
FIGURE 26 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY DIAGNOSIS, 2023
FIGURE 27 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY DIAGNOSIS, 2024-2031 (USD THOUSAND)
FIGURE 28 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY DIAGNOSIS, CAGR (2024-2031)
FIGURE 29 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY DIAGNOSIS, LIFELINE CURVE
FIGURE 30 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY SITE, 2023
FIGURE 31 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY SITE, 2024-2031 (USD THOUSAND)
FIGURE 32 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY SITE, CAGR (2024-2031)
FIGURE 33 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY SITE, LIFELINE CURVE
FIGURE 34 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY AGE GROUP, 2023
FIGURE 35 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY AGE GROUP, 2024-2031 (USD THOUSAND)
FIGURE 36 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY AGE GROUP, CAGR (2024-2031)
FIGURE 37 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY AGE GROUP, LIFELINE CURVE
FIGURE 38 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY END USER, 2023
FIGURE 39 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY END USER, 2024-2031 (USD THOUSAND)
FIGURE 40 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY END USER, CAGR (2024-2031)
FIGURE 41 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY END USER, LIFELINE CURVE
FIGURE 42 MIDDLE EAST AND AFRICA MULTIPLE HEREDITY EXOSTOSIS MARKET: SNAPSHOT (2023)
FIGURE 43 MIDDLE EAST AND AFRICA MULTIPLE HEREDITARY EXOSTOSIS MARKET: COMPANY SHARE 2023 (%)
研究方法
数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。该阶段包括通过各种来源和策略获取市场信息或相关数据。它包括提前检查和规划从过去获得的所有数据。它同样包括检查不同信息源中出现的信息不一致。使用市场统计和连贯模型分析和估计市场数据。此外，市场份额分析和关键趋势分析是市场报告中的主要成功因素。要了解更多信息，请请求分析师致电或下拉您的询问。
DBMR 研究团队使用的关键研究方法是数据三角测量，其中包括数据挖掘、数据变量对市场影响的分析和主要（行业专家）验证。数据模型包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、专利分析、定价分析、公司市场份额分析、测量标准、全球与区域和供应商份额分析。要了解有关研究方法的更多信息，请向我们的行业专家咨询。
可定制
Data Bridge Market Research 是高级形成性研究领域的领导者。我们为向现有和新客户提供符合其目标的数据和分析而感到自豪。报告可定制，包括目标品牌的价格趋势分析、了解其他国家的市场（索取国家列表）、临床试验结果数据、文献综述、翻新市场和产品基础分析。目标竞争对手的市场分析可以从基于技术的分析到市场组合策略进行分析。我们可以按照您所需的格式和数据样式添加您需要的任意数量的竞争对手数据。我们的分析师团队还可以为您提供原始 Excel 文件数据透视表（事实手册）中的数据，或者可以帮助您根据报告中的数据集创建演示文稿。
